JP2016530316A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530316A5
JP2016530316A5 JP2016542091A JP2016542091A JP2016530316A5 JP 2016530316 A5 JP2016530316 A5 JP 2016530316A5 JP 2016542091 A JP2016542091 A JP 2016542091A JP 2016542091 A JP2016542091 A JP 2016542091A JP 2016530316 A5 JP2016530316 A5 JP 2016530316A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition according
water
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016542091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530316A (ja
JP6612234B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/055132 external-priority patent/WO2015038736A2/en
Publication of JP2016530316A publication Critical patent/JP2016530316A/ja
Publication of JP2016530316A5 publication Critical patent/JP2016530316A5/ja
Application granted granted Critical
Publication of JP6612234B2 publication Critical patent/JP6612234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016542091A 2013-09-16 2014-09-11 Cgrp受容体アンタゴニストのための製剤 Active JP6612234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361878183P 2013-09-16 2013-09-16
US61/878,183 2013-09-16
PCT/US2014/055132 WO2015038736A2 (en) 2013-09-16 2014-09-11 Formulations for cgrp receptor antagonists

Publications (3)

Publication Number Publication Date
JP2016530316A JP2016530316A (ja) 2016-09-29
JP2016530316A5 true JP2016530316A5 (enExample) 2017-10-19
JP6612234B2 JP6612234B2 (ja) 2019-11-27

Family

ID=52666511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016542091A Active JP6612234B2 (ja) 2013-09-16 2014-09-11 Cgrp受容体アンタゴニストのための製剤

Country Status (13)

Country Link
US (3) US20160220552A1 (enExample)
EP (2) EP3915561A1 (enExample)
JP (1) JP6612234B2 (enExample)
KR (3) KR20220108207A (enExample)
CN (2) CN112545981A (enExample)
AU (1) AU2014318741B2 (enExample)
BR (1) BR112016005589B8 (enExample)
CA (1) CA2923426A1 (enExample)
IL (1) IL244356B (enExample)
MX (1) MX384611B (enExample)
RU (1) RU2690006C2 (enExample)
SA (1) SA516370737B1 (enExample)
WO (1) WO2015038736A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487706B (zh) * 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
KR20230107902A (ko) 2014-02-05 2023-07-18 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2021005497A1 (en) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CN119350337A (zh) * 2024-12-24 2025-01-24 药康众拓(北京)医药科技有限公司 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739393B2 (en) * 1998-03-19 2001-10-11 Merck Sharp & Dohme Corp. Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations
GB9815801D0 (en) * 1998-07-21 1998-09-16 Merck & Co Inc Liquid polymeric compositions for controlled released bioactive substances
ITRM20020357A1 (it) * 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑

Similar Documents

Publication Publication Date Title
JP2016530316A5 (enExample)
RU2016114537A (ru) Композиции антагонистов рецепторов cgrp
JP2013523677A5 (enExample)
JP2012025755A5 (enExample)
JP2015519330A5 (enExample)
JP2013510124A5 (enExample)
JP2015512938A5 (enExample)
JP2013523676A5 (enExample)
JP2015091877A5 (enExample)
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
RU2017101833A (ru) Орально распадающийся пленочный препарат, содержащий тадалафил, и способ его приготовления
JP2014240439A5 (enExample)
JP2012072150A5 (enExample)
JP2013545785A5 (enExample)
RU2014105585A (ru) Быстрорастворимая фармацевтическая композиция
RU2017146716A (ru) Способ образования наночастиц циклоспорина а/ циклодекстрина
JP2013542264A5 (enExample)
RU2013112807A (ru) Композиция для доставки активных агентов в желудок
JP2008533007A5 (enExample)
JP2015535243A5 (enExample)
JP2016531895A5 (enExample)
JP2016512210A5 (enExample)
JP2016513625A5 (enExample)
MX391096B (es) Formulación liposomal.
RU2016106907A (ru) Мгновенно смачивающаяся пероральная пленочная лекарственная форма без поверхностно-активного вещества или полиспирта